Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03333057 · ClinicalTrials.gov registry record · Phase 2
Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2 study, sponsored by Novaliq.
- Completed
- Registry status
- Phase 2
- Development phase
- 336
- Enrollment target
NCT03333057 is a Phase 2 study that has completed, run by Novaliq. The registered enrollment target is 336 participants.
The verdict
NCT03333057, a Phase 2 study, has completed, sponsored by Novaliq.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 336 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy, safety and tolerability of perfluorohexyloctane (NOV03) at two different dosing regimens compared to saline solution in subjects with Dry Eye Disease (DED).
Interventions
- DRUG Placebo
- DRUG NOV03
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 336 participants |
| Start Date | 2018-01-03 |
| Est. Completion | 2018-07-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03333057
The ClinicalTrials.gov registry entry for NCT03333057 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 336 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novaliq, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03333057 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03333057 about?
NCT03333057 is a clinical study titled "Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)". This study will evaluate the efficacy, safety and tolerability of perfluorohexyloctane (NOV03) at two different dosing regimens compared to saline solution in subjects with Dry Eye Disease (DED).
What is the current status of trial NCT03333057?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 336 participants. The study started on 2018-01-03. Estimated completion is 2018-07-27.
What interventions are being tested in trial NCT03333057?
The interventions under investigation include: Placebo (DRUG), NOV03 (DRUG).
Who is sponsoring clinical trial NCT03333057?
This trial is sponsored by Novaliq, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.